Medical Laboratory Science, Faculty of Applied Medical Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Regenerative Medicine Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Int J Mol Sci. 2024 Aug 7;25(16):8619. doi: 10.3390/ijms25168619.
Alzheimer's disease (AD) is a neurodegenerative disease that is known to accumulate amyloid-β (Aβ) and tau protein. Clinical studies have not identified pathogenesis mechanisms or produced an effective cure for AD. The Aβ monoclonal antibody lecanemab reduces Aβ plaque formation for the treatment of AD, but more studies are required to increase the effectiveness of drugs to reduce cognitive decline. The lack of AD therapy targets and evidence of an association with an acute neuroinflammatory response caused by several bacteria and viruses in some individuals has led to the establishment of the infection hypothesis during the last 10 years. How pathogens cross the blood-brain barrier is highly topical and is seen to be pivotal in proving the hypothesis. This review summarizes the possible role of the gut microbiome in the pathogenesis of AD and feasible therapeutic approaches and current research limitations.
阿尔茨海默病(AD)是一种神经退行性疾病,已知其会积累淀粉样蛋白-β(Aβ)和tau 蛋白。临床研究尚未确定发病机制,也没有针对 AD 产生有效的治疗方法。Aβ单克隆抗体 lecanemab 可减少 Aβ斑块的形成,用于治疗 AD,但需要更多的研究来提高药物疗效,以减少认知能力下降。AD 治疗靶点的缺乏以及与某些个体中几种细菌和病毒引起的急性神经炎症反应有关的证据,导致在过去 10 年中提出了感染假说。病原体如何穿过血脑屏障是一个非常热门的话题,并且被认为是证明该假说的关键。本综述总结了肠道微生物组在 AD 发病机制中的可能作用,以及可行的治疗方法和当前研究的局限性。